Literature DB >> 35305234

A Systematic Review of Host Genomic Variation and Neuropsychological Outcomes for Pediatric Cancer Survivors.

Rella Kautiainen1, Holly Aleksonis1, Tricia Z King2.   

Abstract

Pediatric survivors of brain tumors and acute lymphoblastic leukemia (ALL) are at risk for long-term deficits in their neuropsychological functioning. Researchers have begun examining associations between germline single nucleotide polymorphisms (SNPs), which interact with cancer treatment, and neuropsychological outcomes. This review synthesizes the impact of treatment-related toxicity from germline SNPs by neuropsychological domain (i.e., working memory, processing speed, psychological functioning) in pediatric survivors. By focusing on specific neuropsychological domains, this review will examine outcome measurement and critique methodology. Fourteen studies were identified and included in this review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). All studies were published in peer-reviewed journals in English by November 24th, 2021. Reviewed studies were not of sufficient quality for a meta-analysis due to varying measurement strategies, gaps in reported descriptive variables, and low power. All neuropsychological domains evaluated in this review had associations with SNPs, except fine motor and visual integration abilities. Only five SNPs had consistent neuropsychological findings in more than one study or cohort. Future research and replication studies should use validated measures of discrete skills that are central to empirically validated models of survivors' long-term outcomes (i.e., attention, working memory, processing speed). Researchers should examine SNPs across pathophysiological pathways to investigate additive genetic risk in pediatric cancer survivors. Two SNPs were identified that confer resiliency in neuropsychological functioning, and future work should investigate resiliency genotypes and their underlying biological mechanisms.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Cancer; Cognition; Medulloblastoma; Neuropsychological outcomes; Pediatric; Single-nucleotide polymorphism; Survivors; Treatment-related toxicity

Year:  2022        PMID: 35305234     DOI: 10.1007/s11065-022-09539-2

Source DB:  PubMed          Journal:  Neuropsychol Rev        ISSN: 1040-7308            Impact factor:   7.444


  55 in total

1.  Double Dissociation of Auditory Attention Span and Visual Attention in Long-Term Survivors of Childhood Cerebellar Tumor: A Deterministic Tractography Study of the Cerebellar-Frontal and the Superior Longitudinal Fasciculus Pathways.

Authors:  Alyssa S Ailion; Tricia Z King; Simone R Roberts; Brian Tang; Jessica A Turner; Christopher M Conway; Bruce Crosson
Journal:  J Int Neuropsychol Soc       Date:  2020-04-28       Impact factor: 2.892

Review 2.  Cerebellar-Subcortical-Cortical Systems as Modulators of Cognitive Functions.

Authors:  Sarah V Clark; Eric S Semmel; Holly A Aleksonis; Stephanie N Steinberg; Tricia Z King
Journal:  Neuropsychol Rev       Date:  2021-01-29       Impact factor: 7.444

3.  Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real.

Authors:  Andreas A Argyriou; Konstantinos Assimakopoulos; Gregoris Iconomou; Fotini Giannakopoulou; Haralabos P Kalofonos
Journal:  J Pain Symptom Manage       Date:  2010-09-15       Impact factor: 3.612

4.  Cognitive and adaptive outcome in low-grade pediatric cerebellar astrocytomas: evidence of diminished cognitive and adaptive functioning in National Collaborative Research Studies (CCG 9891/POG 9130).

Authors:  Dean W Beebe; M Douglas Ris; F Daniel Armstrong; John Fontanesi; Raymond Mulhern; Emi Holmes; Jeffrey H Wisoff
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

Review 5.  Childhood Brain Tumors: a Systematic Review of the Structural Neuroimaging Literature.

Authors:  Alyssa S Ailion; Kyle Hortman; Tricia Z King
Journal:  Neuropsychol Rev       Date:  2017-06-23       Impact factor: 7.444

6.  Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

Authors:  Nadia Barahmani; Sarah Carpentieri; Xio-Nan Li; Tao Wang; Yumei Cao; Laura Howe; Lindsay Kilburn; Murali Chintagumpala; Ching Lau; M Fatih Okcu
Journal:  Neuro Oncol       Date:  2008-10-24       Impact factor: 12.300

7.  Adaptive functioning of childhood brain tumor survivors following conformal radiation therapy.

Authors:  Jason M Ashford; Kelli L Netson; Kellie N Clark; Thomas E Merchant; Victor M Santana; Shengjie Wu; Heather M Conklin
Journal:  J Neurooncol       Date:  2014-05       Impact factor: 4.130

Review 8.  Long-term health status among survivors of childhood cancer: does sex matter?

Authors:  Gregory T Armstrong; Charles A Sklar; Melissa M Hudson; Leslie L Robison
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

9.  Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study.

Authors:  Julienne Brackett; Kevin R Krull; Michael E Scheurer; Wei Liu; Deo Kumar Srivastava; Marilyn Stovall; Thomas E Merchant; Roger J Packer; Leslie L Robison; M Fatih Okcu
Journal:  Neuro Oncol       Date:  2012-06-01       Impact factor: 13.029

10.  Association of genes ARID5B, CEBPE and folate pathway with acute lymphoblastic leukemia in a population from the Brazilian Amazon region.

Authors:  Darlen Cardoso Carvalho; Alayde Vieira Wanderley; Fernando Augusto Rodrigues Mello Junior; André Mauricio Ribeiro Dos Santos; Luciana Pereira Colares Leitão; Tatiane Piedade de Souza; Amanda de Nazaré Cohen Lima de Castro; Leandro Lopes de Magalhães; Marianne Rodrigues Fernandes; João Augusto Nunes de Carvalho Junior; André Salim Khayat; Sidney Santos; Paulo Pimentel de Assumpção; Ney Pereira Carneiro Dos Santos
Journal:  Leuk Res Rep       Date:  2019-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.